Trial Profile

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Venetoclax (Primary)
Indications Acute myeloid leukaemia; Cancer; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
Focus Adverse reactions; Registrational
Sponsors AbbVie; AbbVie Germany

Most Recent Events

03 Dec 2024 Planned End Date changed from 27 Feb 2026 to 1 Feb 2026.
03 Dec 2024 Planned primary completion date changed from 27 Feb 2026 to 1 Feb 2026.
17 Jun 2024 Planned End Date changed from 27 May 2025 to 27 Feb 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com